RxDoctor Payments Data

Kelly Olsen, DO

Urology · Mount Laurel, NJNPI 1407340433

Payments from drug & device makers

$3,423in general payments, 2019–2025

Across 51 payments — averaging $67.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$755
  • Olympus Corporation Of The Americas$754
  • Medical Device Business Services, Inc.$245
  • Olympus America Inc.$223
  • Procept Biorobotics Corporation$190
  • Janssen Scientific Affairs, LLC$183
  • plus $1K from 12 others

What the payments were for

  • Travel & lodging$59517%
  • Food & beverage$2,49473%
  • Education$33510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,423 in reported general payments places this provider in the 60th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$204,719
Medicare patients
586
Services billed
4,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron66$42,720
GemtesaVibegron47$30,496
Estradiol53$2,480
Methenamine Hippurate33$1,924
Tolterodine Tartrate ErTolterodine Tartrate28$1,455
Oxybutynin Chloride ErOxybutynin Chloride77$1,402
Tamsulosin Hcl122$1,246
Trospium Chloride27$1,162
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst37$1,052
Finasteride64$514
Ciprofloxacin Hcl82$462
CefuroximeCefuroxime Axetil34$318
Solifenacin Succinate12$282
Oxybutynin Chloride11$190
NitrofurantoinNitrofurantoin Macrocrystal13$160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$115$42,72066 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 401 urology providers in New Jersey.

Other urology in Mount Laurel

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →